JP2023537078A5 - - Google Patents

Info

Publication number
JP2023537078A5
JP2023537078A5 JP2023509418A JP2023509418A JP2023537078A5 JP 2023537078 A5 JP2023537078 A5 JP 2023537078A5 JP 2023509418 A JP2023509418 A JP 2023509418A JP 2023509418 A JP2023509418 A JP 2023509418A JP 2023537078 A5 JP2023537078 A5 JP 2023537078A5
Authority
JP
Japan
Application number
JP2023509418A
Other languages
Japanese (ja)
Other versions
JPWO2022034044A5 (https=
JP2023537078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/072203 external-priority patent/WO2022034044A1/en
Publication of JP2023537078A publication Critical patent/JP2023537078A/ja
Publication of JPWO2022034044A5 publication Critical patent/JPWO2022034044A5/ja
Publication of JP2023537078A5 publication Critical patent/JP2023537078A5/ja
Pending legal-status Critical Current

Links

JP2023509418A 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体 Pending JP2023537078A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063862P 2020-08-10 2020-08-10
US63/063,862 2020-08-10
US202063112104P 2020-11-10 2020-11-10
US63/112,104 2020-11-10
PCT/EP2021/072203 WO2022034044A1 (en) 2020-08-10 2021-08-09 Sars-cov-2 antibodies for treatment and prevention of covid-19

Publications (3)

Publication Number Publication Date
JP2023537078A JP2023537078A (ja) 2023-08-30
JPWO2022034044A5 JPWO2022034044A5 (https=) 2024-07-25
JP2023537078A5 true JP2023537078A5 (https=) 2024-07-25

Family

ID=77595513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509418A Pending JP2023537078A (ja) 2020-08-10 2021-08-09 COVID-19を治療及び防止するためのSARS-CoV-2抗体

Country Status (11)

Country Link
US (2) US20220041694A1 (https=)
EP (1) EP4192860A1 (https=)
JP (1) JP2023537078A (https=)
KR (1) KR20230045613A (https=)
CN (1) CN116234577A (https=)
AU (1) AU2021325339A1 (https=)
BR (1) BR112023002234A2 (https=)
CA (1) CA3190280A1 (https=)
IL (1) IL300257A (https=)
TW (1) TW202221025A (https=)
WO (1) WO2022034044A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
JP2025514858A (ja) 2022-04-29 2025-05-09 アストラゼネカ・ユーケイ・リミテッド SARS-CoV-2抗体、及びその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
CN103540600B (zh) 2003-01-22 2017-12-01 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
JP2008539753A (ja) 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾fc領域およびfc受容体との結合変更を有する抗原結合分子
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
RU2017107847A (ru) * 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
FI4045533T3 (fi) * 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
AU2021275361A1 (en) * 2020-05-17 2023-01-19 Astrazeneca Uk Limited SARS-CoV-2 antibodies and methods of selecting and using the same

Similar Documents

Publication Publication Date Title
CN306085621S (https=)
CN305531273S (https=)
CN305531935S (https=)
CN305532071S (https=)
CN305539124S (https=)
CN305541858S (https=)
CN305571059S (https=)
CN305575168S (https=)
CN305577230S (https=)
CN305577400S (https=)
CN305581568S (https=)
CN305593888S (https=)
CN305594911S (https=)
CN305606033S (https=)
CN305608377S (https=)
CN305609941S (https=)
CN305635831S (https=)
CN305635905S (https=)
CN305636564S (https=)
CN305637947S (https=)
CN305639652S (https=)
CN305645148S (https=)
CN305654811S (https=)
CN305681768S (https=)
CN305684362S (https=)